Benzinga··Vandana SinghNanobiotix Shoots Down J&J Acquisition Rumors, Stock Soars on Clarity
Nanobiotix denies J&J acquisition rumors, shares rise 6.17%. Stock up 774.83% annually; reaffirms focus on advancing cancer pipeline, NBTXR3 partnership.
JNJNBTXcancer treatmentbiotechnology